Variability in primary Sjögren's syndrome is driven by interferon alpha, and genetically associated with the class II HLA DQ locus.

Date publication

juin 2022

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas , Dr DUMORTIER Hélène , Pr GOTTENBERG Jacques-Eric

Tous les auteurs :
Trutschel D, Bost P, Mariette X, Bondet V, Llibre A, Posseme C, Charbit B, Thorball CW, Jonsson R, Lessard CJ, Felten R, Ng WF, Chatenoud L, Dumortier H, Sibilia J, Fellay J, Brokstad KA, Appel S, Tarn Dr JR, Murci LQ, Mingueneau M, Meyer N, Duffy D, Schwikowski B, Gottenberg JE,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35726083

Résumé

Primary Sjögren's syndrome (pSS) is the second most frequent systemic autoimmune disease affecting 0.1% of the general population. To characterize the molecular and clinical variability across pSS patients, we integrated transcriptomic, proteomic, cellular and genetic data with clinical phenotypes in a cohort of 351 pSS patients.

Référence

Arthritis Rheumatol. 2022 06 20;: